Melphalan Hydrochloride Kit
NDC Package 67184-0618-2
Package Information
Melphalan Hydrochloride kits is melphalan Hydrochloride for Injection is indicated for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate. This formulation utilizes a kit delivery system. Marketed by Qilu Pharmaceutical Co., Ltd., this product is identified by NDC 67184-0618 and is authorized under FDA application ANDA211463.
Identification & Billing
- RxCUI: 311487 - melphalan 50 MG Injection
- RxCUI: 311487 - melphalan (as melphalan hydrochloride) 50 MG Injection
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 67184 - Qilu Pharmaceutical Co., Ltd.
- 67184-0618 - Melphalan Hydrochloride
- 67184-0618-2 - 1 KIT in 1 CARTON * 15 mL in 1 VIAL, SINGLE-DOSE (67184-0616-1) * 10 mL in 1 VIAL, SINGLE-USE (67184-0617-1)
- 67184-0618 - Melphalan Hydrochloride
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 67184-0618-2 identifies a specific commercial package of 1 kit in 1 carton * 15 ml in 1 vial, single-dose (67184-0616-1) * 10 ml in 1 vial, single-use (67184-0617-1) of Melphalan Hydrochloride, a human prescription drug labeled by Qilu Pharmaceutical Co., Ltd.. This kit is formulated for intravenous use and contains as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Qilu Pharmaceutical Co., Ltd. on December 18, 2023. The current certification is valid through December 31, 2026.
How is this Qilu Pharmaceutical Co., Ltd. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 67184061802. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.